Literature DB >> 15135556

Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.

Andrew B Scholey1, Andrew C Parrott, Tom Buchanan, Thomas M Heffernan, Jonathan Ling, Jacqui Rodgers.   

Abstract

Recreational Ecstasy/MDMA (3,4-methylenedioxymethamphetamine) users often take a variety of psychoactive drugs, but there is little empirical data on how these drug consumption patterns change with greater experience of Ecstasy. The aim of this study was to compare the polydrug usage patterns reported by non-Ecstasy users, novice Ecstasy users, moderate Ecstasy users, and heavy Ecstasy users. In a WWW study of 763 unpaid volunteers, 481 had never taken Ecstasy, whereas 282 reported they had taken it. The Ecstasy users comprised 109 novice users (1-9 occasions), 136 moderate Ecstasy users (10-99 occasions), and 36 heavy Ecstasy users (+100 occasions). Each participant also reported their experience with a range of other psychoactive drugs. The Ecstasy users reported significantly greater psychoactive drug usage than the non-Ecstasy users. The novice, moderate, and heavy Ecstasy users also differed significantly from each other in the use of cocaine, amphetamine, LSD, and psilocybin mushrooms, but not of alcohol, cannabis, or cigarettes/nicotine. Experienced Ecstasy users also took significantly more MDMA tablets on each occasion, and reported a higher maximum weekly intake. The increased use of Ecstasy is associated with more intensive patterns of Ecstasy/MDMA intake, and the greater use of illicit CNS stimulants and hallucinogens, but not of alcohol, nicotine, or cannabis. These results are discussed in the context of cross-tolerance and drug predisposition/preference.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135556     DOI: 10.1016/j.addbeh.2004.02.022

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  44 in total

1.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).

Authors:  A C Parrott; J Rodgers; T Buchanan; A B Scholey; T Heffernan; J Ling
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

3.  Ethanol and MDMA: a comment on the paper by Izco et al.

Authors:  Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

4.  3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory.

Authors:  Jessica A Able; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  Biol Psychiatry       Date:  2005-12-01       Impact factor: 13.382

5.  Understanding recreational ecstasy use in the United States: a qualitative inquiry.

Authors:  Masuma Bahora; Claire E Sterk; Kirk W Elifson
Journal:  Int J Drug Policy       Date:  2008-02-20

6.  (+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks.

Authors:  Matthew R Skelton; Jessica A Able; Curtis E Grace; Nicole R Herring; Tori L Schaefer; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  Neuropharmacology       Date:  2008-07-12       Impact factor: 5.250

7.  Poly-Drug Use among Ecstasy Users: Separate, Synergistic, and Indiscriminate Patterns.

Authors:  M Boeri; C Sterk; M Bahora; K Elifson
Journal:  J Drug Issues       Date:  2008-04

8.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

9.  Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study.

Authors:  Gerry Jager; Maartje M de Win; Hylke K Vervaeke; Thelma Schilt; Rene S Kahn; Wim van den Brink; Jan M van Ree; Nick F Ramsey
Journal:  Psychopharmacology (Berl)       Date:  2007-05-03       Impact factor: 4.530

10.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.